The effect of riboflavin supplementation on Faecalibacterium prausnitzii in Crohn's disease

Completed

• Conditions: Crohn's disease; M. Crohn; 10017969; 10003816

• Registration Number: NL-OMON41902
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 84

Inclusion Criteria

Group 1 (n=42)
- Patients diagnosed with Crohn*s Disease in remission (Calprotectin < 200 µg/g)
- Age 18-65 years;Group 2 (n=42)
- Patients diagnosed with Crohn*s Disease with active disease (Calprotectin > 200 µg/g)
- Age 18-65 years

Exclusion Criteria

- Swallowing disorders
- Pregnancy and lactation
- Use of antibiotic drugs, probiotics (i.e.Yakult, Vifit, Activia etc) or specific prebiotic supplements in the 3 weeks prior to the riboflavin intervention (for a list of probiotic, prebiotic and other supplements see attachment 2)
- Use of Methotrexate drugs.
- Colonoscopy and colon cleansing in last 3 months
- Use of a vitamin B2 supplement, or multivitamin complexes containing vitamin B (i.e. vitamin B-complex) in the 3 weeks prior to the riboflavin intervention
- Severe Crohn*s disease (HBI > 12)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1). To investigate the effect of a riboflavin supplement on the number of F.<br /><br>prausnitzii bacteria in the faeces of active and quiescent Crohn*s disease<br /><br>patients.</p><br>